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ABSTRACT 
Metastasis is the fatal weapon for most cancer. Through access to the vascular and 
lymphatic systems, cancer is able to spread to vital organs throughout the body. 
This is made possible by the degradation of basement membranes and cleavage of 
the extracellular matrix. Matrix metalloproteinases are the enzymes that are 
responsible for both of the aforementioned tasks. Two matrix metalloproteinases, 
MMP-2 and MMP-9, are zinc dependent enzymes that have roles in tumor 
progression through their involvement with the degradation of the ECM. Specific 
enzymes such as these are viable anti-cancer targets. This thesis evaluates the use of 
a metallodrug, which consists of a metal binding motif, a linker, and a target 
recognition domain to target these enzymes. Carbonic anhydrase, a well-studied 
enzyme in the literature, was used as a model to design the metallodrugs. The 
results of this project show that the metallodrug shows promise as a therapeutic 
against carbonic anhydrase, and through modification could be used to inhibit and 
inactivate matrix metalloproteinases as well. 
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INTRODUCTION 
Tumor progression and metastasis is the fatal step for most cancer. Metastasis is the 
cause of 90% of solid tumor fatalities1. Cancer originates as a single tumor and is 
spread throughout the body utilizing the vascular and lymphatic systems created 
through angiogenesis. Angiogenesis is the creation of new blood vessels from old or 
pre-existing blood vessels. This physiological process is essential in wound healing 
as well as in the metastasis of cancer. Many enzymes play an active role in tumor 
progression. One such family, matrix metalloproteinases have shown proteolytic 
activity linking them to this progression. 
 
The matrix metalloproteinase family currently has 24 structurally related members. 
The most explored link to cancer is their function of breaking down and cleaving 
components off of the extracellular matrix (ECM) as well as other basement 
membranes. Through this function, cancer cells have access to entering the stromal 
matrix. The activity of these enzymes are not just limited to the degradation of the 
ECM, but also reduction of apoptosis in cancer cells, destruction of chemokine 
gradients, and activation of various growth factors2. 
 
Much work was originally put towards development of MMP inhibitors (MMPIs). 
Many of these passed early evaluation and immediately went into clinical trials 
where poor results proved discouraging.  However, most of these early tests were 
conducted using broad-spectrum inhibitors, inhibiting multiple MMP’s.  Certain 
MMP’s demonstrate a more positive correlation between proteolytic activity and 
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cancer progression. The initial early trials were focused on late and advanced stage 
cancer patients, whereas early studies showed that MMPI’s would be most effective 
with early stage patients3. 
 
Not all early trials produced discouraging results. One such trial involved patients 
with gastric carcinoma who were treated with marimastat resulting in an increase 
in patients that survived two or more years3. New approaches that are more 
selective compared to old methods should have increased success. Targeting 
specific MMP’s and their substrates can accomplish this.  
 
This project looks at specifically targeting MMP-2 and MMP-9. These two matrix 
metalloproteinases are both correlated with cancer progression. Tumor 
angiogenesis requires the degradation of the basement membrane and extracellular 
matrix surrounding blood vessels, followed by chemotaxis of endothelial cells, the 
proliferation of endothelial cells, 
and finally reformation of the 
basement membrane along with 
new blood vessel growth4. 
 
Traditional drugs display high 
affinity, but reversible binding to 
a therapeutic target.  The goal is 
to inhibit the function of the target (normally a protein). However, activity is 
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These key points differentiate the activity of catalytic metallodrugs, from high 
affinity binding that is essential for the classical inhibitory mechanism of drugs 
currently on the market.  High affinity binding of the targeting domain may not be 
desirable from the viewpoint of facile release of the metallodrug following 
inactivation of the target.  Optimization of the binding affinity of the targeting 
domain is an issue that will need to be considered on a case-by-case basis.  High 
affinity binding to the target clearly has desirable traits, but may be unnecessary 
with the catalytic metallodrug concept described here. 
 
Low molecular weight compounds could 
be cleared quickly from the serum.  A 
peptide design for ligands that could, if 
necessary, be extended to the formation of 
fusion proteins (joining the ATCUN motif 
(Fig. 3) to a larger stabilizing protein partner) with the active peptide located at the 
N-terminus through a peptide linker, or in the case of non-peptide molecules by 
conjugation to other large stabilizing polymers. The clearance of such high 
molecular weight molecules would be considerably slower.  To deal with potential 
instability toward protease digestion, the introduction of D-amino acid forms could 
be instituted. 
 
The enzyme carbonic anhydrase is well characterized throughout the literature. 
Carbonic anhydrase helps to maintain the pH of the blood as well as to rid tissue of 
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carbon dioxide. It accomplishes this task by converting carbon dioxide and water to 
bicarbonate and protons. It also is useful in the reverse of this task in converting 
protons and bicarbonate into carbon dioxide and water. Carbonic anhydrase is a 
zinc dependent enzyme, just like MMP-2. Literature has found similarities between 
the active sites and thus many common inhibitors10. This allows carbonic anhydrase 
to serve as a cost effective model system for studying inhibitors as was conducted in 
this study. 
 
EXPERIMENTAL AND DATA ANALYSIS 
Synthesis of Therapeutic Agents 
The targeting domain, 4-carboxybezene sulfonamide was obtained from Sigma 
Aldrich. The amidated peptide, KGH was obtained from NEO Biosciences. The 
peptide was quantified through the use of a metal titration to ensure stock quantity. 
DMSO was first dried prior to use through the use of molecular sieves. The targeting 
domain, 4-carboxybenzene sulfonamide was dissolved in 60-μL DMSO at a 
concentration of 100 mM. Next, KGH was then added to this solution for a 
concentration of 100 mM as well. Next, N-hydroxysuccinimide (NHS) was added to 
the solution for a concentration of 200 mM NHS. The final reagent, the carbodiimide 
EDC was added at a concentration of 200 mM to the solution. The reaction was 
allowed to react at room temperature for 24 hours. 
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Figure 4. Coupling Reaction Scheme (KGH-amide + 4-carboxybenzene sulfonamide) 
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Following the 24 hour reaction period, the reaction was diluted to 600 μL with 
nano-pure water to ensure that the DMSO concentration was 10%. The completed 
reaction was then separated by High Performance Liquid Chromatography (HPLC). 
A reverse phase C18 monomeric column was used. The A-eluent was water with 
0.1% TFA. The B-eluent was acetonitrile with 0.1% TFA. The eluent gradient can be 
seen below in figure 5. 
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Fig. 5. HPLC Gradient 
Time 
(min) 
0 2 3 10 50 60 70 
%B 0 0 10 10 40 100 100 
%A 100 100 90 90 60 0 0 
 
 The wavelength 280 nm was monitored as this is where the aromatic ring of the 
sulfonamide can be observed. The collected aliquots were lyophilized and then 
analyzed by ESI mass spectrometry. 
 
Buffer Preparation 
Two different Tris buffers were used throughout the compound synthesis and 
enzyme assays. The first contained 12.5 mM Tris-Hydrochloride and 50 mM NaCl 
that was adjusted to a pH of 7.4. The second buffer contained 50 mM Tris 
Hydrochloride and 150 mM NaCl that was adjusted to a pH of 7.4. 
 
Nickel Titration 
The compound was then suspended in 500 µL of Tris buffer (12.5 mM, 75 mM NaCl) 
and analyzed for concentration through a nickel titration. The estimated 
concentration of the solution was around 1 mM. The compound was diluted ten-fold 
using Tris buffer (12.5 mM, 75 mM NaCl). Nickel chloride (1 mM) was titrated into 
the solution in 2 µL increments. The increment was mixed and allowed to incubate 
for five minutes. An absorbance scan was then run from 200 to 600 nm. Points from 
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absorbance at 245 nm were fit to quantify the concentration. The inflection point 
was regarded as the concentration in which nickel to ligand was in a one to one ratio. 
 
CA-II Binding Assay 
The Km of hydrolysis of 4-nitrophenyl acetate by carbonic anhydrase is 3.88 mM8. 
The IC-50 value was first determined for the targeting compound, 4-
carboxybenzene sulfonamide. The activity of the enzyme at a concentration of 2 µM 
per individual run was monitored for two minutes at 400 nm in the presence of 4-
carboxybenzene sulfonamide between the concentrations of 0.04-80 µM for two 
minutes. The slope of the initial velocity for each concentration was found and fit to 
a logistic equation to find the IC-50 values. This same procedure was done for the 
coupled product 4-carboxybenzene sulfonamide KGH, except that the concentration 
of inhibitor used ranged from 0.4-13.5 µM. The coupled product was also incubated 
with equal amounts of copper for 30 minutes and run with the same concentrations. 
Controls of free copper and nickel were also run to find IC-50 values. The 
concentration of copper (II) chloride used ranged from 10-1000 µM. The range of 
nickel (II) chloride ranged from 100-1500 µM. 
 
Enzyme Inactivation 
The inactivation reaction of the enzyme was conducted in 100 µL Tris buffer (50 
mM, 150 mM NaCl) with CA-II (7.5 µM), Cu-KGH 4-carboxybenzene sulfonamide 
product (0.605 µM), hydrogen peroxide (1 mM), and ascorbate (1 mM). The copper 
was allowed to incubate with KGH 4-carboxybenzene sulfonamide for 30 minutes 
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prior to addition. From this reaction, 10 µL was taken and combined in a cuvette 
with 90 µL of 4-nitrophenyl acetate (1.1 mM) in Tris buffer (50 mM, 150 mM NaCl). 
The reaction was monitored at 400 nm at 1, 10, 20, 40, 60, 90, and 120 minute 
increments. The following controls were run simultaneously: 
1. Enzyme and Substrate 
2. Enzyme, Substrate, and Catalyst 
3. Ascorbate, Hydrogen Peroxide, and Substrate 
4. Enzyme, Substrate and Catalyst. 
The slope of each initial velocity from each two minute run was found and fit to a 
graph. 
 
MMP-2 Buffer and Km Determination 
The buffer used with MMP-2 contained 50 mM Tris, 10 mM CaCl2, 150 mM NaCl, and  
0.05% (w/v) Brij 35. The pH was adjusted to 7.5. The Km was measured by 
incubating a fixed concentration of enzyme (1.41 nM) with varying concentrations 
of substrate (1-50 µM). The fluorogenic peptide substrate, MCA-Pro-Leu-DPA-Ala-
Arg-NH2 was acquired from R&D Systems. The Km was measured using a 
fluorescence plate reader and 96 well plates. The solution was excited at 300 nm for 
an emission at 405 nm. The reaction was allowed to run for 60 min, but the slope of 
the initial velocity was found from the first eight minutes of the reaction.  
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MMP-2 Binding Assay 
An IC-50 assay was run for 4-carboxybenzene sulfonamide with MMP-2. Similar 
concentrations of inhibitor that were used for CA-II were used in this assay (0.01-
100 µM) with a fixed concentration of MMP-2 (1.41 nM). The reaction was excited at 
300 nm and the emission at 405 nm was measured. The slope of the velocity after 
eight minutes was plotted on a graph.  
 
RESULTS 
The coupling reaction of 4-carboxybenzene sulfonamide resulted in a yield of 7.8%. 
This produced a sufficient amount of inhibitor to run the chemical analysis. The 
separation by HPLC can be seen in figure 6. The product came out of the HPLC 
between 24.6 and 25.6 minutes. The lyophilized product was then further analyzed 
by ESI. The peak at 523.3 and 262.1 correspond to the product. The ESI spectrum 
can be seen in figure 7. Following re-suspension the product concentration was 0.93 
mM. The titration was conducted using a ten-fold dilution and can be seen in figure 
8. 
Figure 6. HPLC Separation 
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Figure 7. ESI Analysis 
 
Figure 8. Determination of Product Concentration by Nickel Titration 
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found to be 1.8±0.3 µM. Graphs displaying the IC-50 values can be found in figures 9, 
10, and 11. The IC-50 value for copper was found to be 87±7 µM. The IC-50 value for 
nickel was 2400±300 µM. The IC-50 data for the free metal controls can be found in 
figure 13. 
Figure 9. IC-50 4-carboxybenzene sulfonamide 
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Figure 10. IC-50 Metal Free KGH 4-carboxybenzene sulfonamide 
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Figure 11. IC-50 Cu-KGH 4-carboxybenzene sulfonamide 
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Figure 12. IC-50 Free Metal Controls 
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The time dependent inactivation with the metal bound catalyst resulted in a two-
fold increase in inactivation when compared to the co-reagents. The initial velocities 
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for the assay containing the enzyme, substrate, hydrogen peroxide, ascorbate, and 
Cu-KGH 4-carboxybenzene sulfonamide can be seen in figure 14. The slopes of the 
time dependent inactivation of the enzyme along with the controls is plotted in 
figure 14. 
Figure 13. Initial Velocities of the Time Dependent Inactivation of CA-II 
 
 
 
 
 
 
 
 
 
Figure 14. Time Dependent Inactivation of CA-II 
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The KM of MMP-2 was found to be 18±2 µM. The initial velocities as well as the 
change in relative fluorescence over time can be seen in figure 15. 
Figure 15. KM Determination 
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       Vmax 41± 2 ΔRFI/min 
Km 18± 2 µM 
Binding assays were run with 4-carboxybenzene sulfonamide and MMP-2. IC-50 
values could not be elucidated in the µM range. This data can be seen in figure 16. 
Figure 16. IC-50 MMP-2 and 4-carboxybenzene sulfonamide 
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DISCUSSION 
The preliminary tests of compounds with carbonic anhydrase produced promising 
data of an effective, competitively binding compound. The binding did not change 
extensively from the targeting domain to the coupled compound indicating that the 
metal domain did not produce negative steric interactions within the active site. The 
IC-50 of the coupled Cu-KGH 4-carboxybenzene sulfonamide product was 1.8 µM. In 
the presence of peroxide and ascorbate, a decrease in enzyme activity is seen. This is 
further enhanced in the presence of the metal complex, a two-fold enhancement. It 
is interesting that the metal complex needs the co-reagents present. The initial 
inactivation of just the metal complex returns to baseline without the presence of 
co-reagents. A potential mechanism can be hypothesized from these results. In the 
presence of just peroxide and ascorbate, it can be hypothesized that hydroxyl 
radicals  or other reactive oxygen species are produced, but with the addition of the 
metal complex, it either further facilitates this production or the chemistry is more 
mediated from the metal to the enzyme. Future studies by mass spectrometry could 
help to elucidate a mechanism for inactivation of this process. 
 
The IC-50 for 4-carboxybenzene sulfonamide for carbonic anhydrase did not carry 
over to MMP-2. As evidenced by figure 12, competitive binding was not observed. 
This could be due to a different method or location of binding within the MMP-2 
enzyme. This suggests that the binding of 4-carboxybenzene sulfonamide to 
carbonic anhydrase may utilize a different structure that is not present within the 
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active site of MMP-2 or is sterically blocked. Although this project did not determine 
any effective inhibitors for MMP-2, it paved the way in answering many initial 
questions about the design of a possible metallodrug against MMP-2. 
 
Future work could utilize this same design with different comparative inhibitors. 
Literature indicates that hydroxamates have shown effective inhibition of MMP-2. 
This may be a future avenue to pursue as a possible targeting domain10.  
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